Beta Bionics Statistics
Total Valuation
Beta Bionics has a market cap or net worth of $668.39 million. The enterprise value is $548.15 million.
Important Dates
The next estimated earnings date is Tuesday, May 6, 2025, before market open.
Earnings Date | May 6, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Beta Bionics has 42.86 million shares outstanding.
Current Share Class | 42.86M |
Shares Outstanding | 42.86M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | +23.74% |
Owned by Insiders (%) | 3.16% |
Owned by Institutions (%) | 13.24% |
Float | 41.34M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 3.00 |
Forward PS | 7.45 |
PB Ratio | 18.31 |
P/TBV Ratio | n/a |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 10.34 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.62, with a Debt / Equity ratio of 0.22.
Current Ratio | 4.62 |
Quick Ratio | 3.82 |
Debt / Equity | 0.22 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -711.95 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | n/a |
Return on Invested Capital (ROIC) | n/a |
Return on Capital Employed (ROCE) | -51.33% |
Revenue Per Employee | $182,247 |
Profits Per Employee | -$190,708 |
Employee Count | 291 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
Beta (5Y) | n/a |
52-Week Price Change | n/a |
50-Day Moving Average | n/a |
200-Day Moving Average | n/a |
Relative Strength Index (RSI) | 19.89 |
Average Volume (20 Days) | 338,391 |
Short Selling Information
The latest short interest is 945,109, so 2.21% of the outstanding shares have been sold short.
Short Interest | 945,109 |
Short Previous Month | 209,284 |
Short % of Shares Out | 2.21% |
Short % of Float | 2.29% |
Short Ratio (days to cover) | 0.05 |
Income Statement
In the last 12 months, Beta Bionics had revenue of $53.03 million and -$55.50 million in losses. Loss per share was -$4.89.
Revenue | 53.03M |
Gross Profit | 29.26M |
Operating Income | -40.58M |
Pretax Income | -55.50M |
Net Income | -55.50M |
EBITDA | -39.37M |
EBIT | -40.58M |
Loss Per Share | -$4.89 |
Full Income Statement Balance Sheet
The company has $60.90 million in cash and $7.30 million in debt, giving a net cash position of $53.60 million or $1.25 per share.
Cash & Cash Equivalents | 60.90M |
Total Debt | 7.30M |
Net Cash | 53.60M |
Net Cash Per Share | $1.25 |
Equity (Book Value) | 32.87M |
Book Value Per Share | -34.35 |
Working Capital | 64.68M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$40.34 million and capital expenditures -$3.15 million, giving a free cash flow of -$43.49 million.
Operating Cash Flow | -40.34M |
Capital Expenditures | -3.15M |
Free Cash Flow | -43.49M |
FCF Per Share | -$1.01 |
Full Cash Flow Statement Margins
Gross margin is 55.17%, with operating and profit margins of -76.52% and -104.64%.
Gross Margin | 55.17% |
Operating Margin | -76.52% |
Pretax Margin | -104.64% |
Profit Margin | -104.64% |
EBITDA Margin | -74.24% |
EBIT Margin | -76.52% |
FCF Margin | n/a |
Dividends & Yields
Beta Bionics does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | n/a |
Shareholder Yield | n/a |
Earnings Yield | -9.22% |
FCF Yield | -7.23% |
Analyst Forecast
The average price target for Beta Bionics is $26.67, which is 71.02% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $26.67 |
Price Target Difference | 71.02% |
Analyst Consensus | Strong Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Beta Bionics has an Altman Z-Score of -4.06 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -4.06 |
Piotroski F-Score | 1 |